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Studies involving Monte Carlo simulations are common in both diagnostic and therapy medical phy-
sics research, as well as other fields of basic and applied science. As with all experimental studies,
the conditions and parameters used for Monte Carlo simulations impact their scope, validity, limita-
tions, and generalizability. Unfortunately, many published peer-reviewed articles involving Monte
Carlo simulations do not provide the level of detail needed for the reader to be able to properly assess
the quality of the simulations. The American Association of Physicists in Medicine Task Group #268
developed guidelines to improve reporting of Monte Carlo studies in medical physics research. By
following these guidelines, manuscripts submitted for peer-review will include a level of relevant
detail that will increase the transparency, the ability to reproduce results, and the overall scientific
value of these studies. The guidelines include a checklist of the items that should be included in the
Methods, Results, and Discussion sections of manuscripts submitted for peer-review. These guideli-
nes do not attempt to replace the journal reviewer, but rather to be a tool during the writing and
review process. Given the varied nature of Monte Carlo studies, it is up to the authors and the review-
ers to use this checklist appropriately, being conscious of how the different items apply to each partic-
ular scenario. It is envisioned that this list will be useful both for authors and for reviewers, to help
ensure the adequate description of Monte Carlo studies in the medical physics literature. © 2017
American Association of Physicists in Medicine [https://doi.org/10.1002/mp.12702]
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Monte Carlo methods are a powerful alternative to experimental
work in many areas of research. As such, the use of Monte
Carlo-based computer simulations has become commonplace
in both diagnostic and therapy medical physics. The increase in
computer power available over the past decades has contributed
to the increasing number and complexity of the simulations per-
formed to answer critical questions in our research field. How-
ever, as with actual experiments, the design of a Monte Carlo-
based computer simulation and selection of its parameter values
can result in large variations in the final results, potentially
allowing for important biases to be introduced inadvertently.
Therefore, judging the appropriateness of a simulation from the
description of the methods used in a peer-reviewed article is
important, but at the same time increasingly challenging.
In light of this, the American Association of Physicists in
Medicine formed Task Group #268 to develop guidelines to
improve reporting of Monte Carlo studies in medical physics
research. This initiative was inspired by similar guidelines set
forth for clinical studies, such as the STARD guidelines for
reporting diagnostic studies1,2 and the CONSORT guidelines
for reporting randomized trials,3,4 among others. The intent of
this Task Group was to increase the level of relevant detail of
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descriptions used in these studies, which should in turn increase
the level of transparency, the ability to reproduce results, and
the overall scientific value of these studies. To accomplish this
goal, this Task Group developed a checklist of the items that
should be included in the Methods, Results and Discussion sec-
tion of manuscripts submitted for peer review that include
Monte Carlo simulations. As such, it is envisioned that this list
will be useful both for authors and for reviewers, to help ensure
the adequate description of Monte Carlo studies in the medical
physics literature. It should be noted that this checklist is drafted
so as to be applicable to studies using any Monte Carlo soft-
ware, both publicly available and developed in-house.
Note, however, that the omission of any of the items listed
in the checklist should not be automatically taken as disquali-
fying. Given the nature of Monte Carlo simulations, there
might be scenarios in which some items are either not appli-
cable, are irrelevant, or have no significant impact on the
study. Therefore, ultimately it is up to the authors and the
reviewers to use this checklist appropriately, being conscious
of how the different items apply to each particular study.
It is important to note that it is beyond the scope of this
work to specify how Monte Carlo studies should be per-
formed. The correct design, implementation, validation, and
performance of a Monte Carlo-based study involve careful
consideration of many issues which are usually highly depen-
dent on the application being studied. It is the hope of this
Task Group that improving and homogenizing the information
provided regarding the study will allow reviewers and readers
to better determine its appropriateness, or lack thereof.
In addition to the checklist itself (Table I), the Task Group
proposes a template table (Table II) for possible inclusion in
the Methods section of manuscripts. The use of this proposed
table would allow for the inclusion of many of the checklist
items with short phrases and/or references to previous work.
The items from Table I that are included in this methodology
summary table are denoted with a (*). If Table II is used, the
checklist items that are not included in it should be included
in text form in the manuscript, in the appropriate sections.
As can be seen in Table I, various items (e.g., variance
reduction techniques, statistical uncertainty estimation)
include the need to either describe the method or technique
used, or to provide references. When a well-documented,
public domain Monte Carlo code is used and the referenced
method or feature is used with no modification, then software
manuals or related publications that provide detailed descrip-
tions of method can be cited, eliminating the need for detailed
explanations in the article body. However, if a method was
developed or modified by the authors, then a detailed descrip-
tion or reference to previous work should be included.
EXPLANATORY NOTES ON CHECKLIST ITEMS
Items #4 and #17: The extent to which the simulation needs
to be validated and the methods used to achieve this will vary
considerably depending on the situation. Ideally, experimental
validation with conditions representative of those being
investigated should be or have been performed, but this is not
always feasible or necessary. Replication of previously pub-
lished results, either experimental or simulations, is often suffi-
cient. For example, where relevant, the AAPM Task Group
Report #195 could be used for partial, or where appropriate,
complete validation.5 Reference to previous publications that
include the validation(s) performed for the code used and/or
description(s) of the new simulation(s) or the experiment(s)
performed for validation should be described in the Methods
section (Item #4). The results of any new validation efforts
should be reported in the table suggested in Table II and/or in
the Results section (Item #17). Studies related to simulation
efficiency, e.g., presenting new GPU-based code or a new vari-
ance reduction technique, in addition to the information listed
below regarding timing (Item #5), should include a comprehen-
sive comparison of results against the original code to ensure
consistency. This will necessitate the testing with various
parameter values.
Item #5: For studies related to simulation efficiency, tim-
ing, and/or introduction of a new code or algorithm whose
main benefit is increase in computation efficiency, e.g., a
new GPU-based Monte Carlo code, then results and timing
should be provided for a range of conditions, to better gauge
the benefits and limitations of the algorithm presented. It is
important to specify how different parameters affect the effi-
ciency. This is especially the case for GPU-based code, where
the advantages of parallelization may depend strongly on
some simulation parameters in more complex ways than
those usually seen for CPU-based code.
For other studies, computation time, at least in order of
magnitude, should be specified to provide the readers with an
idea of how long such a simulation takes to perform.
Item #6: The composition and geometrical descriptions of
some components of a simulated system may be proprietary in
nature, and the investigators’ access to this information gov-
erned by a nondisclosure agreement, precluding its publica-
tion. This should not, by itself, compromise the publishability
of such studies. However, in some cases it is possible (and if
acceptable to the rights holder) to describe proprietary compo-
nents in terms of equivalent or approximate system characteris-
tics that reproduce the relevant behavior of the proprietary system
components. For example, the influence of a proprietary x-ray
beam transport system (tube, housing, filters, etc.) may be
described in terms of equivalent thickness of aluminum filtration.
When available, such equivalent descriptions of proprietary sys-
tem components should be provided and justified.
Item #7: For simulation geometries that include a vox-
elized model obtained from computed tomography images,
the method to convert from voxel image intensities, e.g.,
Hounsfield Units, to material composition and density should
be described, and a reference provided, if applicable. The
voxel size used should be specified. If different voxel sizes
are used for geometry specification and for scoring, then all
sizes should be specified and the method used to resample
should be reported.
Item #8: Information on the source to be provided could
include, but not be limited to, type of particle or radiation,
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shape, energy and its distribution including bin size, and
direction, distribution and modulation of emission, etc.
Item #9: Specification of relevant cross-sections used for
the simulations should be provided. If the default options of
the Monte Carlo simulation code are used, the libraries
involved should be listed and referenced. As examples, the
following is a short sample of the type of information
required, as relevant per the particles and energies involved:
• For low-energy photons (< 200 keV): photoelectric
cross-section library. For high atomic number materials,
atomic relaxation data source should be referenced.
TABLE I. Guidelines for Publications of Monte Carlo Studies: Checklist of the items that should be included in papers in which Monte Carlo calculations are
involved. Where possible, items denoted with a (*) may be included in a Methodology table using the template presented in Table II. For items 4 and 5, which
have options a and b, depending on the nature of the study, usually only one of the alternatives should be used.
Section
and topic No Item
Title
1 Identification as a Monte Carlo study
Methods
Software 2* Name of Monte Carlo software used, including a reference to a paper and/or report describing the package, if available. If the
selected code is not commonly used for the application of the current study or if it necessitated considerable modification, then
justification for why a certain Monte Carlo code was selected
3* Release number and/or release date of Monte Carlo software used
4a* If the code has been previously validated or is being validated against previous publications, description of the code’s validation in
similar or at least relevant applications, preferably via references
4b* If code is being validated against experimental measurements, then detailed description of experimental conditions and of simulation
study. For the latter, include any assumptions and simplifications of the experimental conditions
Hardware 5a* If study is related to Monte Carlo efficiency, specification of CPU/GPU time, compiler information, and system used to perform the
simulations, including CPU/GPU model number
5b* Otherwise specification of order of magnitude of CPU/GPU time and CPU/GPUmodel number
Geometry 6 Description of simulation geometry, using drawings and tables as needed. Provide all relevant dimensions which are not proprietary
and non-disclosable. If possible, provide equivalent composition and dimension information in place of non-disclosable proprietary
details
Materials 7 Description of material composition and mass density of each item in the geometry, with references if applicable. Provide the
elemental composition and/or, if applicable, the Hounsfield Units conversion method
Source 8* Description of the source, including: source of phase-space files if used; model used to generate source; and model parameter
values. Provide reference, if applicable
Physics
and transport
9* Specification of the cross-section data used along with derived quantities such as stopping powers
10* Specification of relevant transport parameters used, such as energy and particle weight cutoffs, step sizes and thresholds. Also
transport algorithms if there is more than one option for the code used. Specifying use of the default is adequate if it is unique and
documented by citation
11* Specification of variance reduction (VRT) and approximate efficiency improvement techniques (AEIT) used, and their parameters.
References describing them or specific descriptions of any new techniques should be included if they are not included in the Monte
Carlo software as built-in, documented options
Scoring 12* Specification of the relevant scored quantities. Provide tally names if using a standard Monte Carlo software that includes them, but
also include what physical quantity is scored by the tally. When results are binned, tabulated values should make clear what the
variable means, e.g., the mid-point, top or range of a bin
13* Number of histories and number of source particles used. If various simulations involve different numbers of histories and source
particles, at least provide range
14* Description and references, as appropriate, of the method used to estimate statistical uncertainty, including if estimated by the
history-by-history or the batch method
Analysis 15* Description of how scored quantities are normalized and/or converted to other metrics. List physical conversion factors used and
provide references, if applicable, if there are multiple values for these in the literature
16* Description of how scored quantities are de-noised or otherwise filtered, with references, if applicable. If none, then this should be
specifically mentioned
Results
17* Results of validation, unless code has been previously validated
18* Scored quantities with statistical uncertainty including a specification of the confidence limits used. In general, graphical
representation of results such as depth-dose curves or spectra should be histogram rather than point plots, and include uncertainty
estimates with error bars in the graphs or text in the caption
Discussion
19 Discussion of study limitations, including sources of potential bias, statistical uncertainty, and generalizability
20 Discussion of assumptions and approximations and their potential effect on the results, given the knowledge gained
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• For kerma approximation and track-length estimators:
mass-energy absorption coefficient data source, which
should be compatible with cross-sections used for pho-
ton transport.
• For x-ray imaging receptor simulations: atomic/molecu-
lar form factor data and total linear attenuation coeffi-
cient data and inelastic scattering data model used.
Item #10: Data on transport parameters should be pro-
vided and referenced, where appropriate. As examples, a
short sample of specifications that should possibly be pro-
vided are:
• Specify if charged particles are transported.
• Specify transport package used and transport physics
used, with references, as appropriate. Providing a refer-
ence to the default packages/options used may be
enough as long as that is unique for the particular code.
Otherwise, values of charged-particle transport parame-
ters should be supplied.
• For response simulations of detectors with gaseous cav-
ities, boundary crossing algorithms should be specified
and a relevant Fano cavity benchmarking study refer-
enced.
Item #12: If the scored dose to the medium is being con-
verted to dose to water either on-the-fly or after the simula-
tion, specify the methods used and justify them.
Item #13: Commonly, a history is formed by one primary
particle, emitted from the source, and all the secondary parti-
cles generated by it. On some occasions, however, it may be
convenient to consider several primary particles as forming
part of the same history. An example of the latter is when the
1.17 MeV and the 1.33 MeV photons emitted after the disin-
tegration of a Co-60 nucleus are to be considered in
conjunction in order to reproduce the sum peak in a spec-
trometer; here the quantity of interest is the total energy
deposited in the spectrometer by both photons and all their
descendants. Another example is when using a phase-space
source from an accelerator where many particles may corre-
spond to one initial electron. All of these primary particles
from the phase space are part of the same history. Similarly,
if particle splitting is used as a VRT with a phase-space
source, all the split particles are part of one history. Given
these possible scenarios, when appropriate, listing of both the
number of histories and the number of source particles is
specified in this Item. That said, the specific number of histo-
ries is not as important as the statistical uncertainty on the
scored quantities since the number can be meaningless given
the effects of VRTs.
Item #15: In most cases, the scored quantity or quantities
resulting from the Monte Carlo simulations are normalized to
some measurable quantity (often used to experimentally cali-
brate the system) and might also be converted to a different
quantity. For example, in mammographic dosimetry simula-
tions, the resulting energy deposition in the breast tissue
might be converted to normalized glandular dose by multiply-
ing by the G factor (the ratio of mass-energy absorption coef-
ficients of glandular tissue to that of the breast tissue
mixture) and dividing by the glandular tissue mass and the
incident air kerma. The source of these physical values (e.g.,
mass-energy absorption coefficients, incident air kerma) or
the values used (e.g., glandular tissue mass), should be pro-
vided. Other examples include correction factors employed
for detector response calculations, such as intrinsic energy
dependence or other precalculated detector corrections.
Item #16: Smoothing or de-noising algorithms applied to
the Monte Carlo simulation results should be specified, along
with all relevant algorithm parameters used. If the results are
not filtered in any way, then this should be specifically stated.
The use of Monte Carlo simulations in medical physics
has become commonplace, and continuing advances in com-
puter power can be expected to only increase the use and
complexity of these studies. As with any other studies, Monte
Carlo-based simulation studies need to be clearly and com-
prehensively described to allow for the evaluation of their
validity, appropriateness, generalizability and limitations. It is
hoped that the guidelines and recommendations in this
AAPM Task Group Report will be useful for authors and for
reviewers of Monte Carlo-based manuscripts in their efforts.
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